Safety of selective cyclooxygenase-2-inhibitors in inflammatory bowel disease.
Stenson
William F
WF
Department of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri, USA.
D001168:Arthritis / Q000188:drug therapy* / Q000209:etiology*; D000075202:Contraindications; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000009:adverse effects / Q000627:therapeutic use*
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases